Valmet (VALMT) AGM 2026 summary

Opening remarks and agenda

• Meeting arrangements, voting procedures and technical instructions were provided, with simultaneous interpretation available.

Board and executive committee updates

• The Board met 13 times, with 95% attendance, focusing on strategy renewal and operating model changes.

• CEO Thomas Hinnerskov, 19 months into the role, was commended for energetic leadership and cultural transformation.

• Eight Board members re-elected through the 2027 AGM: Pekka Vauramo (Chair), Annika Paasikivi (Vice-Chair), Anu Hämäläinen, Pekka Kemppainen, Annareetta Lumme-Timonen, Monika Maurer, Bernd Eikens and Jonas Gustavsson.

• Audit Committee: Anu Hämäläinen (Chair), Bernd Eikens, Pekka Kemppainen and Annareetta Lumme-Timonen; People and Remuneration Committee: Annika Paasikivi (Chair), Jonas Gustavsson, Monika Maurer and Pekka Vauramo.

• Juha Pöllänen invited to participate in Board meetings as personnel representative and expert for the Board’s term.

Financial performance review

• Orders received fell 11% to EUR 5,216 million, mainly due to a tough comparison year in biomaterials; net sales remained steady.

• Comparable EBITDA margin reached a record 11.9%, up 60 basis points from 2024; Process Performance Solutions posted a 19.6% margin, while Biomaterial Solutions and Services maintained 10.3%.

• EUR 35 million in cost savings realized from operating model changes, with EUR 80 million expected in total; cash flow was EUR 581 million and the balance sheet remained robust.